Cargando…

Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells

BACKGROUND: Activins control the growth of several tumour types including thoracic malignancies. In the present study, we investigated their expression and function in malignant pleural mesothelioma (MPM). METHODS: The expression of activins and activin receptors was analysed by quantitative PCR in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoda, M A, Münzker, J, Ghanim, B, Schelch, K, Klikovits, T, Laszlo, V, Sahin, E, Bedeir, A, Lackner, A, Dome, B, Setinek, U, Filipits, M, Eisenbauer, M, Kenessey, I, Török, S, Garay, T, Hegedus, B, Catania, A, Taghavi, S, Klepetko, W, Berger, W, Grusch, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3516694/ https://www.ncbi.nlm.nih.gov/pubmed/23169291 http://dx.doi.org/10.1038/bjc.2012.519

Ejemplares similares

Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma
por: Ghanim, B, et al.
Publicado: (2014)

Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study
por: Ghanim, B, et al.
Publicado: (2015)

High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma
por: Hoda, Mir Alireza, et al.
Publicado: (2016)

Expression of FGFR1–4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity
por: Vlacic, Gregor, et al.
Publicado: (2019)

The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma
por: Laszlo, Viktoria, et al.
Publicado: (2018)

Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma
por: Klikovits, Thomas, et al.
Publicado: (2017)

Circulating FGF18 is decreased in pleural mesothelioma but not correlated with disease prognosis
por: Mosleh, Berta, et al.
Publicado: (2023)

Erythropoietin Receptor Expression Is a Potential Prognostic Factor in Human Lung Adenocarcinoma
por: Rózsás, Anita, et al.
Publicado: (2013)

Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis
por: Kirschner, Michaela B, et al.
Publicado: (2015)

Inhibin/activin expression in human and rodent liver: subunits α and βB as new players in human hepatocellular carcinoma?
por: Frost, K, et al.
Publicado: (2011)

Apelin promotes lymphangiogenesis and lymph node metastasis
por: Berta, Judit, et al.
Publicado: (2014)

KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis
por: Lohinai, Zoltan, et al.
Publicado: (2017)

Impact of fibrinogen levels and modified Glasgow prognostic score on survival of stage III/N2 non-small cell lung cancer patients treated with neoadjuvant therapy and radical resection
por: Sinn, Katharina, et al.
Publicado: (2022)

Corrigendum to ‘Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study’: [ESMO Open Volume 7, Issue 2, April 2022, 100466]
por: Sinn, K., et al.
Publicado: (2022)

Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study
por: Brcic, Luka, et al.
Publicado: (2021)

Controversies in oncology: surgery for small cell lung cancer? It’s time to rethink the case
por: Hoda, Mir Alireza, et al.
Publicado: (2018)

Prenylation Inhibition-Induced Cell Death in Melanoma: Reduced Sensitivity in BRAF Mutant/PTEN Wild-Type Melanoma Cells
por: Garay, Tamás, et al.
Publicado: (2015)

Clinical and prognostic implications of CD47 and PD-L1 expression in surgically resected small-cell lung cancer
por: Lang, C., et al.
Publicado: (2022)

Malignant pleural mesothelioma nodules remodel their surroundings to vascularize and grow
por: Kovacs, Ildiko, et al.
Publicado: (2022)

Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors
por: Torok, Szilvia, et al.
Publicado: (2017)

Primary and hTERT-Transduced Mesothelioma-Associated Fibroblasts but Not Primary or hTERT-Transduced Mesothelial Cells Stimulate Growth of Human Mesothelioma Cells
por: Ries, Alexander, et al.
Publicado: (2023)

Mesothelioma-associated fibroblasts enhance proliferation and migration of pleural mesothelioma cells via c-Met/PI3K and WNT signaling but do not protect against cisplatin
por: Ries, Alexander, et al.
Publicado: (2023)

Management of malignant pleural mesothelioma – part 1: epidemiology, diagnosis, and staging: Consensus of the Austrian Mesothelioma Interest Group (AMIG)
por: Geltner, Christian, et al.
Publicado: (2016)

A link between the fibroblast growth factor axis and the miR‐16 family reveals potential new treatment combinations in mesothelioma
por: Schelch, Karin, et al.
Publicado: (2017)

EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib
por: Buder, Anna, et al.
Publicado: (2020)

YB-1 Knockdown Inhibits the Proliferation of Mesothelioma Cells through Multiple Mechanisms
por: Johnson, Thomas G., et al.
Publicado: (2020)

Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study
por: Sinn, K., et al.
Publicado: (2022)

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells
por: Molnár, Eszter, et al.
Publicado: (2018)

KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy
por: Ghimessy, Áron Kristof, et al.
Publicado: (2019)

Histone Deacetylase Inhibitor Treatment Increases the Expression of the Plasma Membrane Ca(2+) Pump PMCA4b and Inhibits the Migration of Melanoma Cells Independent of ERK
por: Hegedüs, Luca, et al.
Publicado: (2017)

A comparison of sample preparation strategies for biological tissues and subsequent trace element analysis using LA-ICP-MS
por: Bonta, Maximilian, et al.
Publicado: (2016)

Systemic Activin Is Elevated in Patients With Severe Alcoholic Hepatitis
por: STAUDACHER, J. J., et al.
Publicado: (2022)

The optogenetic promise for oncology: Episode I
por: Ingles-Prieto, Alvaro, et al.
Publicado: (2014)

Activin E is a TGFβ ligand that signals specifically through activin receptor-like kinase 7
por: Vestal, Kylie A, et al.
Publicado: (2023)

Management of malignant pleural mesothelioma – part 3: Data from the Austrian Mesothelioma Interest Group (AMIG) database
por: Klikovits, Thomas, et al.
Publicado: (2016)

Variations in activin receptor, inhibin/activin subunit and follistatin mRNAs in human prostate tumour tissues
por: Schaik, R H N van, et al.
Publicado: (2000)

Management of malignant pleural mesothelioma—part 2: therapeutic approaches: Consensus of the Austrian Mesothelioma Interest Group (AMIG)
por: Hoda, Mir Alireza, et al.
Publicado: (2016)

The orphan ligand, activin C, signals through activin receptor-like kinase 7
por: Goebel, Erich J, et al.
Publicado: (2022)

Prognostic impact of activin subunit inhibin beta A in gastric and esophageal adenocarcinomas
por: Staudacher, J. J., et al.
Publicado: (2022)

Xnrs and Activin Regulate Distinct Genes during Xenopus Development: Activin Regulates Cell Division
por: Ramis, Joana M., et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_0fjtg5dj3mehg049kd7f26n4dh